PLACE OF LAPATINIB IN THE THERAPY OF HER2-POSITIVE BREAST CANCER


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Speaking about the advances in the treatment of HER2-positive breast cancer (BC), it should be understood that the sum of this success is appeared possible due to gradual application of different options for anti-HER-treatment in monotherapy, in combination with the various regimens of chemotherapy and endocrine therapy, combination of different anti-HER-drugs. Each of the currently available anti-HER-drugs should has its place at the right population and at the right time. Lapatinib - a small molecule, reversible inhibitor of ErbBI (EGF) and ErbB2 (HER2) receptors with an intracellular mechanism of action. Selection of the optimal location of the drug use depends on the rate of progression of the disease, sensitivity to the prior trastuzumab-containing therapy, and the general state of the patient. In case of co-expression of steroid receptors in the tumor of HER2-positive breast cancer, combination of lapatinib with an aromatase inhibitor remains the best option for patients with primary unresectable locally advanced or metastatic breast cancer, including in the 1st-line therapy. With the progression during or after trastuzumab-containing therapy, especially in BC patients with non-aggressive course of the disease, one of the most effective treatment options is a combination of lapatinib with capecitabine (at the earlier stages), or (in most pretreated patients) with trastuzumab.

Full Text

Restricted Access

About the authors

L. G Zhukova

FSBI “RORC n.a. N.N. Blokhin" of RMH

Email: zhukova.lyudmila@rambler.ru
MD, Leading Researcher at the Branch of Chemotherapy and Combined Therapy of Malignant Tumors Moscow

I. P Ganshina

FSBI “RORC n.a. N.N. Blokhin" of RMH

Moscow

V. G Zaitsev

FSBI “RORC n.a. N.N. Blokhin" of RMH

Moscow

M. V Stepanchenko

FSBI “RORC n.a. N.N. Blokhin" of RMH

Moscow

References

  1. Slamon D.J., Eiermann W., Robert N.J., et al. Ten-year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER-2 -positive early breast cancer patients. 2015 San Antonio Breast Cancer Symposium. Abstract S5-04.
  2. Andersson M., Lidbrink E., Bjerre K., Wist E., Enevoldsen K., Jensen A.B., Karlsson P., Tange U.B., Sоrensen P.G., Müller S., Bergh J., Langkjer S.T. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J. Clin. Oncol. 2011;29(3):264-71.
  3. Valero V., Forbes J., Pegram M.D., Pienkowski T., Eiermann W., von Minckwitz G., Roche H., Martin M., Crown J., Mackey J.R., Fumoleau P., Rolski J., Mrsic-Krmpotic Z., Jagiello-Gruszfeld A., Riva A., Buyse M., Taupin H., Sauter G., Press M.F., Slamon D.J. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER-2 -gene-amplified metastatic breast cancer (BCIRG 007 Study): two highly active therapeutic regimens. J. Clin. Oncol. 2011;29(2):149-56.
  4. Slamon DJ., Leyland-Jones B., Shak S., Fuchs H., Paton V, Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus amon oclonal antibody against HER-2 for metastatic breast cancer that over-expresses HER-2. N. Engl. J. Med. 2001;344:783-92.
  5. Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., Tubiana-Hulin M., Chan S., Grimes D., Anton A., Lluch A., Kennedy J., O'Byrne K., Conte P., Green M., Ward C., Mayne K., Extra J.M. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: TheM77001 study group. J. Clin. Oncol. 2005;23(19):4265-74.
  6. Burstein H.J., Keshaviah A., Baron A.D., Hart R.D., Lambert-Falls R., Marcom P.K., Gelman R., Winer E.P. Trastuzumab plus vinorelbine or taxane chemotherapy for HER-2 -overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study. Cancer. 2007;110:965-72.
  7. Jackisch C. HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy. Oncologist. 2006;11(Suppl. 1):34-41.
  8. Minckwitz G., du Bois A., Schmidt M., Maass N., Cufer T., de Jongh F.E., Maartense E., Zielinski C., Kaufmann M., Bauer W., Baumann K.H., Clemens M.R., Duerr R., Uleer C., Andersson M., Stein R.C., Nekljudova V., Loibl S. Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study. J. Clin. Oncol. 2009;27(12):1999-2006.
  9. Segatto O., King C.R., Pierce J.H., Di Fiore P.P., Aaronson S.A. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol. Cell. Biol. 1988;8:5570-74.
  10. Di Fiore P.P., Pierce J.H., Kraus M.H., Segatto O., King C.R., Aaronson S.A. ErbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 1987;237:178-82.
  11. Hayes D.F., Yamauchi H., Broadwater G., Cirrincione C.T., Rodrigue S.P., Berry D.A., Younger J., Panasci L.L., Millard F., Duggan D.B., Norton L., Henderson I.C.; Cancer and Leukemia Group B. Circulating HER-2/erbB-2/c-neu (HER-
  12. extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin. Cancer Res. 2001;7:2703-11.
  13. Wood E.R.,Truesdale A.T.,McDonald O.B.,Yuan D., Hassell A., Dickerson S.H., Ellis B., Pennisi C., Horne E., Lackey K., Alligood K.J., Rusnak D.W., Gilmer T.M., Shewchuk L. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004;64 (18):6652-59.
  14. Xia W., Mullin R.J., Keith B.R., Liu L.H., Ma H., Rusnak D.W., Owens G., Alligood K.J., Spector N.L. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene. 2002;21(41):6255-63.
  15. Rusnak D.W., Lackey K., Affleck K., Wood E.R., Alligood K.J., Rhodes N., Keith B.R., Murray D.M., Knight W.B., Mullin R.J., Gilmer T.M. The effects of the novel, reversible epider-mal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. 2001;1:85-94.
  16. Geyer C., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., Jagiello-Gruszfeld A., Crown J, Chan A, Kaufman B., Skarlos D., Campone M., Davidson N., Berger M., Oliva C., Rubin S.D., Stein S., Cameron D. Lapatinib plus Capecitabine for HER-2 -Positive Advanced Breast Cancer. Engl. J. Med. 2006;355(26):2733-43.
  17. Cameron D., Casey M., Press M., Lindquist D., Pienkowski T., Romieu C.G., Chan S., Jagiello-Gruszfeld A, Kaufman B., Crown J., Chan A., Campone M., Viens P., Davidson N., Gorbounova V., Raats J.I., Skarlos D., Newstat B., Roychowdhury D., Paoletti P., Oliva C., Rubin S., Stein S., Geyer C.E. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastu-zumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat. 2008;112:533-43.
  18. Metro G, Foglietta J., Russillo M., Stocchi L., Vidiri A, Giannarelli D., Crino L., Papaldo P., Mottolese M., Cognetti F., Fabi A., Gori S. Clinical outcome of patients with brain metastases from HER-2-positive breast cancer treated with lapatiniband capecitabine. Ann. Oncol. 2011;22:625-30.
  19. Sutherland S., Ashley S., Miles D., Chan S., Wardley A., Davidson N., Bhatti R., Shehata M., Nouras H., Camburn T., Johnston S.R. Treatment of HER-2 -positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases - the UK experience. Br. J. Cancer. 2010;102:995-1002.
  20. Iwata H., Narabayashi M., Ito Y., Saji S., Fujiwara Y., Usami S., Katsura K., Sasaki Y. A phase II study of lapatinib for brain metastases in patients with HER-2 -overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients. Int. J. Clin. Oncol. 2013;18:621-28.
  21. Lin N.U., Eierman W., Greil R., Campone M., Kaufman B., Steplewski K., Lane S.R., Zembryki D., Rubin S.D., Winer E.P. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER-2 -positive breast cancer brain metastases. J. Neurooncol. 2011;105:613-20.
  22. Жукова Л.Г. Рак молочной железы с тройным негативным фенотипом у российской популяции больных. Клинико-морфологические особенности. Вопр. онкол. 2015;2:189-94.
  23. von Minckwitz G., Untch M., Blohmer J.U., Costa S.D., Eidtmann H., Fasching P.A., Gerber B., Eiermann W., Hilfrich J., Huober J., Jackisch C., Kaufmann M., Konecny G.E., Denkert C., Nekljudova V., Mehta K., Loibl S. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J. Clin. Oncol. 2012;30(15):1796-804.
  24. Kaufman B., Mackey J.R., Clemens M.R., Bapsy P.P., Vaid A., Wardley A., Tjulandin S., Jahn M., Lehle M., Feyereislova A., Rеvil C., Jones A. Trastuzumab plus anastrozole versus anastro-zole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM Study. J. Clin. Oncol. 2009;27:5529-37.
  25. Johnston S., Pippen J.Jr., Pivot X., Lichinitser M., Sadeghi S., Dieras V., Gomez H.L., Romieu G., Manikhas A., Kennedy M.J., Press M.F., Maltzman J., Florance A., O'Rourke L., Oliva C., Stein S., Pegram M. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 2009;27:5538-46.
  26. Chu I., Blackwell K., Chen S., Slingerland J. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation and estrogendependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005;65(1):18-25.
  27. Schwarzberg L.S., Franco S.X., Florance A., O'Rourke L., Maltzman J., Johnston S. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist. 2010;15(2):122-29.
  28. Sherif B.N., Sherrill B., Amonkar M., et al. Lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive HER-2+metastatic breast cancer: a quality-of-life analysis [abstract no. 1039]. J. Clin. Oncol. 2009;27(Suppl. 15):50s. Plus poster presented at the 45th Annual Meeting of the American Society of Clinical. Oncology. 2009 May 29 - Jun 9;Orlando (FL).
  29. Konecny G.E., Pegram M.D., Venkatesan N., Finn R., Yang G., Rahmeh M., Untch M., Rusnak D.W., Spehar G., Mullin R.J., Keith B.R., Gilmer T.M., Berger M., Podratz K.C., Slamon D.J. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated BC cells. Cancer Res. 2006;66:1630-39.
  30. Blackwell K.L., Burstein H.J., Storniolo A.M., Rugo H., Sledge G., Koehler M., Ellis C., Casey M., Vukelja S., Bischoff J., Baselga J., O'Shaughnessy J. Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer. J. Clin. Oncol. 2010;28(7):1124-30.
  31. Blackwell K.L., Burstein H.J., Storniolo A.M., Rugo H.S., Sledge G., Aktan G., Ellis C., Florance A., Vukelja S., Bischoff J., Baselga J., O'Shaughnessy J. Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study. J. Clin. Oncol. 2012;30(21):2585-92.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies